CN106974940A - Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented - Google Patents
Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented Download PDFInfo
- Publication number
- CN106974940A CN106974940A CN201610032106.9A CN201610032106A CN106974940A CN 106974940 A CN106974940 A CN 106974940A CN 201610032106 A CN201610032106 A CN 201610032106A CN 106974940 A CN106974940 A CN 106974940A
- Authority
- CN
- China
- Prior art keywords
- composition
- bacterium
- heavy wall
- probiotics
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 66
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 66
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 19
- 201000010099 disease Diseases 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 208000008589 Obesity Diseases 0.000 claims abstract description 30
- 235000020824 obesity Nutrition 0.000 claims abstract description 29
- 230000037396 body weight Effects 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 230000009467 reduction Effects 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims description 169
- 230000002550 fecal effect Effects 0.000 claims description 54
- 235000013305 food Nutrition 0.000 claims description 27
- 241001464949 Coprococcus eutactus Species 0.000 claims description 25
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 23
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 23
- 241001624700 Dialister invisus Species 0.000 claims description 22
- 102000016267 Leptin Human genes 0.000 claims description 19
- 108010092277 Leptin Proteins 0.000 claims description 19
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 19
- 229940039781 leptin Drugs 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 241000962947 Coprococcus eutactus ATCC 27759 Species 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000192125 Firmicutes Species 0.000 claims description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 claims description 2
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 claims description 2
- 230000008901 benefit Effects 0.000 claims description 2
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 241001478240 Coccus Species 0.000 claims 1
- 238000003304 gavage Methods 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 239000003814 drug Substances 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 244000005700 microbiome Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 8
- -1 trimellitic acid ester Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002068 microbial inoculum Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 4
- 241000281549 Dialister invisus DSM 15470 Species 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 101001063890 Mus musculus Leptin Proteins 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000035611 feeding Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 description 2
- 241001535083 Dialister Species 0.000 description 2
- 241000186394 Eubacterium Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000192031 Ruminococcus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229960000395 phenylpropanolamine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229940002552 xenical Drugs 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- UXQIZNHUXDTSQN-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate;phthalic acid Chemical compound OCCCOC(=O)C=C.OC(=O)C1=CC=CC=C1C(O)=O UXQIZNHUXDTSQN-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 241000511612 Anaerofilum Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ARCGXLSVLAOJQL-UHFFFAOYSA-N anhydrous trimellitic acid Natural products OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000013368 commensalism Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 101150073877 egg-1 gene Proteins 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of application of heavy wall mushroom probiotics in obesity-related disease is treated and prevented, specifically, heavy wall mushroom probiotics of the invention is used to prepare composition or preparation, and the composition or preparation are used for the one or more purposes being selected from the group：(a) prevent and/or treat fat；(b) blood fat is reduced；(c) prevent or treat angiocardiopathy；And/or (d) prevention and/or treatment diabetes.The heavy wall mushroom probiotics of the present invention can significantly reduce body weight, reduction blood fat, reduction body fat ratio.
Description
Technical field
The invention belongs to microbiological art, in particular it relates to which heavy wall mushroom probiotics is treating and preventing fertilizer
Application in fat and its relevant disease, is directed to the composition comprising heavy wall mushroom probiotics and its application.
Background technology
There are a large amount of symbiotic microorganisms in human body, they are largely resided in the enteron aisle of people, and quantity is more than 1,000,000,000,000,000
(1014The order of magnitude), it is more than 10 times of human body cell sum.In very long evolutionary process, enteric microorganism is reached with the mankind
Good cooperation, nutrition, metabolism to human body and it is immune all play vital effect, many researchers be more by
Human body intestinal canal microbiologic population regards one " organ " of human body, or the genome of human body second as, wherein the magnanimity contained
Hereditary information is closely related with human health.By to nearly ten thousand kinds of hundreds of diseases such as diabetes, coronary heart disease, obesity, colon cancer
The research of sample finds that some specific species show significant association with disease, clinical evaluation of these results in disease
A brand-new direction is provided with the therapeutic intervention in diagnosis and later stage.
Obesity is a kind of chronic disease, and many factors can all cause obesity, and its origin of falling ill does not study clear so far.Fertilizer
It is fat while being also a series of inducible factor of diseases, in such as hypertension, diabetes, coronary heart disease, cholecystopathy, osteoarthritis, sleep
Breathing asphyxia, breathing imbalance, hysteroma, prostate cancer, breast cancer and colon cancer etc..According to NIH report, 9700 are there are about at present
Ten thousand Americans are overweight and obesity, wherein the type ii diabetes number related to obesity reaches about 15,100,000 people, every year
It there are about 200,000 people and die from the disease related to obesity.
Body fat is superfluous caused by obesity is often as physiology or biochemical function change.During fat is generally included
Property fat, phosphatide and cholesterol.The increase of fat is due to the consumption that Energy intaking is more than energy.It is fat from nosogenesis
There are two types：(a) simple obesity (simple obesity) and (b) Secondary Obesity (second obesity).Merely
Property obesity can be divided into congenital obesity (idiopamic obesity) and posteriority fat (acquired obesity), it is single
Pure property obese patient quantity can account for more than 95% total fat number.Congenital obesity be caused by substantial amounts of fat cell, and
It is common in obesity in childhood.Posteriority obesity is that caused by larger sized fat cell, and it is fat to be common in the manhood.It is secondary
Property obesity be otherwise known as symptomatic obesity, it is typically caused by endocrine or disease of metabolism.
There are five kinds of strategies for treating obesity at present：Go on a diet, take exercise, behaviour therapy, drug therapy and rehabilitation operation
(therapetltic operation).Take the speed of the main health risk factor and weight loss for regarding patient of which kind of strategy
Depending on effect, it may be selected or combine these strategies and adiposis patient is treated.The speed and effect of its weight loss are by all
Such as influence of age, height, family history and risk factor Multiple factors.Diet-exercise regimen, that is, eat low in calories, low fat
Food and carry out exercising with oxygen, but this method be generally acknowledged that it is unsuccessful to ordinary populace, and need adhere to regularly for a long time；
The effect got instant result can be reached by removing body fat operation, but there are many restrictions, and such as operation risk, grease removal effect is difficult to hold
Long and spend prohibitively expensive etc..
Drug therapy is current main clinical treatment obesity and its method for obesity-related disease (such as diabetes).Medicine
The mechanism for the treatment of includes appetite-suppressing, increase energy expenditure, stimulates mobile fat, the synthesis of reduction triglycerides and suppress fat and inhale
Receive.Main medicine is at present：Phenylpropanolamine (phenylpropanolamine, PPA), Xenical (orlistat, Xenical
III) with Reductil (sibutramine, ReductilTM).The hyperglycaemia of some diabetes patients passes through diet and/or exercise regimen
Or still can not obtain suitable control using above-mentioned therapeutic compounds.For these patients, exogenous insulin should be used.To patient
For, the use of exogenous insulin is costly and painful method, can also bring multiple complications to patient.For example, due to not having
Have and have a meal or abnormal exercise, the calculating mistake of insulin dose can cause insulin response (hypoglycemia).In addition, using medicine
It may also happen that to the locally or systemically allergy or immune resistance of medicine.
A kind of method of current this area also treatment and prevention obesity and its relevant disease without effective, Small side effects
And medicine.
Therefore this area is a kind of new in the urgent need to developing, and has no toxic side effect, for treat and prevent it is fat and its
The medicine of relevant disease.
The content of the invention
It is an object of the present invention to provide heavy wall mushroom probiotics in terms of fat and its relevant disease is treated and prevented
Purposes.
Effectively had no toxic side effect it is a further object of the present invention to provide a kind of, for treating and preventing fat and its phase
Medicine, beverage, the food compositions of related disorders, or animal feed composition.
It is a further object of the present invention to provide a kind of losing weight and/or the method and its application of blood glucose.
First aspect present invention provides a kind of purposes of heavy wall mushroom probiotics, for preparing composition or preparation, institute
State one or more purposes that composition or preparation are used to be selected from the group：(a) prevent and/or treat fat；(b) blood fat is reduced；
(c) prevent or treat angiocardiopathy；And/or (d) prevention and/or treatment diabetes, wherein, the heavy wall mushroom probiotics choosing
From the following group：Association fecal bacteria (Coprococcus eutactus), muddiness wear Alister bacterium (Dialister invisus),
Or its combination.
In another preference, the heavy wall mushroom probiotics includes association fecal bacteria (Coprococcus
eutactus)。
In another preference, the association fecal bacteria (Coprococcus eutactus) is selected from the group：
Coprococcus eutactus ATCC 27759、Coprococcus eutactus ATCC 51897、Coprococcus
Eutactus L2-50 or its combination.
In another preference, the heavy wall mushroom probiotics wears Alister bacterium (Dialister including muddiness
invisus)。
In another preference, the muddiness is worn Alister bacterium (Dialister invisus) and is selected from the group：
Dialister invisus DSM 15470、Dialister invisus E2.20、Dialister invisus E9.48、
Or its combination.
In another preference, the heavy wall mushroom probiotics includes the one or more in table 3.
In another preference, the heavy wall mushroom probiotics is selected from table 3, and from identical or different category.
In another preference, the composition is selected from the group：Food compositions, health composition, pharmaceutical composition, drink
Feed composition, fodder compound or its combination.
In another preference, described composition is oral formulations.
In another preference, described composition is liquid formulation, solid formulation, semisolid preparations.
In another preference, the formulation of described composition is selected from the group：Powder agent, powder, tablet, sugar-coat agent, glue
Wafer, granule, suspending agent, solution, syrup, drops and sublingual lozenge.
In another preference, described food compositions include latex product, solution product, pulverulent product or suspended
Liquid product.
In another preference, described food compositions include dairy products, milk powder or emulsion.
In another preference, described liquid formulation is selected from the group：Solution product or suspension product.
Second aspect of the present invention provides a kind of purposes of heavy wall mushroom probiotics, for preparing composition or preparation, institute
State one or more purposes that composition or preparation are used to be selected from the group：(i) reduction mammal in MCP-
1 (MCP-1) level；And/or (ii) improves leptin resistance, the sensitiveness in vivo to Leptin is improved, wherein, the firmicutes
Class probiotics is selected from the group：Association fecal bacteria (Coprococcus eutactus), muddiness wear Alister bacterium (Dialister
Invisus) or its combination.
In another preference, the composition or preparation are also independently or additionally used for the one kind or many being selected from the group
Plant purposes：
(iii) body weight increase of mammal is suppressed；
(iv) the body fat ratio (the ratio between fat weight/body weight) of mammal is reduced；
(v) blood lipid level of mammal is reduced；
(vi) level of the HDL (HDLC) in mammal is improved；
(vii) low-density lipoprotein (LDLC) level in reduction mammal.
In another preference, the mammal includes people, rodent (such as rat, mouse).
In another preference, it is described reduction mammal blood lipid level include reduction T-CHOL (TC) level and/
Or triglyceride levels.
Third aspect present invention is used for the composition for the treatment of and/or pre- preventing obesity there is provided a kind of, and the composition includes：
(i) the heavy wall mushroom probiotics of safe and effective amount；On (ii) food or pharmaceutically acceptable carrier；Wherein, the heavy wall
Mushroom probiotics is selected from the group：Association fecal bacteria (Coprococcus eutactus), muddiness wear Alister bacterium
(Dialister invisus) or its combination.
In another preference, the heavy wall mushroom probiotics includes association fecal bacteria (Coprococcus
eutactus)。
In another preference, the association fecal bacteria (Coprococcus eutactus) is selected from the group：
Coprococcus eutactus ATCC 27759、Coprococcus eutactus ATCC 51897、Coprococcus
Eutactus L2-50 or its combination.
In another preference, the heavy wall mushroom probiotics wears Alister bacterium (Dialister including muddiness
invisus)。
In another preference, the muddiness is worn Alister bacterium (Dialister invisus) and is selected from the group：
Dialister invisus DSM 15470、Dialister invisus E2.20、Dialister invisus E9.48、
Or its combination.
In another preference, the composition is selected from the group：Food compositions, health composition, pharmaceutical composition, drink
Feed composition, fodder compound or its combination.
In another preference, the composition contains 1 × 10-1 × 1020Cfu/mL or cfu/g heavy wall mushroom is prebiotic
Bacterium, preferably 1 × 104-1×1015Cfu/mL or cfu/g heavy wall mushroom probiotics, by the cumulative volume or total of the composition
Weight meter.
In another preference, in described composition, containing 0.0001-99wt%, preferably described in 0.1-90wt%
Heavy wall mushroom probiotics, with the gross weight meter of the composition.
In another preference, described composition is unit dosage form (an a piece of, capsule or a bottle), each unit
The quality of composition described in formulation is 0.05-5g, preferably 0.1-1g.
In another preference, described composition also contains other probiotics and/or prebiotics.
In another preference, other described probiotics are selected from the group：Lactic acid bacteria, Bifidobacterium, lactobacillus acidophilus or
It is combined.
In another preference, described prebiotics is selected from the group：It is FOS (FOS), galactooligosaccharide (GOS), low
Xylan (XOS), lactosucrose (LACT), soyabean oligosaccharides (SOS), inulin (Inulin) or its combination.
Fourth aspect present invention provides a kind of preparation method of composition described in third aspect present invention, including step：
Mixed by (i) heavy wall mushroom probiotics, with acceptable carrier or pharmaceutically acceptable carrier on (ii) food,
So as to form the composition described in third aspect present invention.
In another preference, described composition is oral formulations.
A kind of method that fifth aspect present invention provides losing weight and/or blood fat, (i) heavy wall is applied to the object
Composition described in mushroom probiotics or third aspect present invention.
In another preference, described administration includes oral.
In another preference, described application dosage is 0.01-5g/50kg body weight/days, it is preferred that 0.1-2g/50kg
Body weight/day.
In another preference, described object includes mammal, such as people.
It should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the invention and have in below (eg embodiment)
It can be combined with each other between each technical characteristic of body description, so as to constitute new or preferred technical scheme.As space is limited, exist
This no longer tires out one by one states.
Brief description of the drawings
Fig. 1 shows body weight increase situation of each group mouse compared with before gavage after gavage association fecal bacteria.
Fig. 2 shows that gavage muddiness wears body weight increase situation of each group mouse compared with before gavage after Alister bacterium.
Fig. 3 shows body weight increase situation of each group mouse compared with before gavage after gavage combination strain.
Fig. 4 shows the body fat ratio of gavage association fecal bacteria each group mouse after 9 weeks.
Fig. 5 shows that gavage muddiness wears the body fat ratio of Alister bacterium each group mouse after 9 weeks.
Fig. 6 shows the body fat ratio of gavage combination strain each group mouse after 9 weeks.
Fig. 7 shows influence of the gavage association fecal bacteria to blood fat.
Fig. 8 shows that gavage muddiness wears influence of the Alister bacterium to blood fat.
Fig. 9 shows influence of the gavage combination strain to blood fat.
Figure 10 shows influence of the gavage association fecal bacteria to monocyte chemoattractant protein-1 (MCP-1).
Figure 11 shows that gavage muddiness wears influence of the Alister bacterium to monocyte chemoattractant protein-1 (MCP-1).
Figure 12 shows influence of the gavage combination strain to monocyte chemoattractant protein-1 (MCP-1).
Figure 13 shows influence of the gavage association fecal bacteria to leptin (Leptin, LEP).
Figure 14 shows that gavage muddiness wears influence of the Alister bacterium to leptin (Leptin, LEP).
Figure 15 shows influence of the gavage combination strain to leptin (Leptin, LEP).
Embodiment
The present inventor is by in-depth study and experiment extensively, it has unexpectedly been found that, association fecal bacteria (Coprococcus
) and/or muddiness wears Alister bacterium (Dialister invisus) and has prevention and treatment fat and its related disease eutactus
The effect of sick (such as angiocardiopathy), by the active compound feeding food experimental subjects containing above-mentioned heavy wall mushroom probiotics, hair
Existing said composition can suppress increased weight, reduce body fat ratio, reduce blood fat, effectively mitigate the illnesss such as cardiovascular and obesity.
The present invention is completed on the basis of this.
As used herein, term " containing " represents that various composition can be applied to the mixture or composition of the present invention together
In.Therefore, term " mainly by ... constitute " and " consist of " are included in term " containing ".
As used herein, described " body fat ratio " refers to the ratio of fat weight/body weight.
The heavy wall mushroom probiotics of the present invention and its application
As used herein, a class Firmicutes of commensalism in described " heavy wall mushroom probiotics of the invention " duodenum 12 road
Bacterium, Gram's staining is positive, shaft-like, such as clostridium XIVa clusters and IV clusters (Clostridium cluster XIVa and IV),
Including fusobacterium (Clostridium), Eubacterium (Eubacterium), Ruminococcus (Ruminococcus) and sulfuric acid
Some kinds of salt reduction Pseudomonas (Anaerofilum) etc..By with other microbial interactions of enteron aisle, such probiotics is in intestines
Played a significant role in road colony balance, meanwhile, also play other specific or required functions.
In the present invention, described " heavy wall mushroom probiotics of the invention " refers to association fecal bacteria (Coprococcus
Eutactus), muddiness wear one or more Pseudomonas of Alister bacterium (Dialister invisus) 2 kinds of Pseudomonas mixing or
One or more mixing of multiple bacterium in each Pseudomonas.
Wherein, association fecal bacteria (Coprococcus eutactus) is a kind of obligate anaerobe, it is impossible to moves, works as presentation
Gram's staining is positive when going out paired or chain pair state, but can fade quickly.Containing fermentable carbohydrate
In culture medium, slightly elongated shape is presented.But the bacterium is generally circular, a diameter of 0.7-1.3 μm.
It is a kind of obligate anaerobe, not movable coccobacillus that muddiness, which wears Alister bacterium (Dialister invisus),
(0.3-0.4 × 0.3-0.6 μm), Gram's staining is negative.Single dispersing morphology can be presented, can also be rendered into, short chain, small
The forms such as cluster.
Fat and its relevant disease (such as angiocardiopathy) is being treated and prevented the invention provides heavy wall mushroom probiotics
The application of aspect.Subject takes in high-fat food, and there is heavy wall mushroom probiotics (i) to suppress subject's increased weight；
(ii) blood fat is reduced；(iii) reduce body fat than ability.According to the preference of the present invention, the firmicutes through the present invention
Class probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can lead obesogenous high fat being fed for treating
The C57BL/6J male mices of the food of fat, compared with not receiving the control group for the treatment of, its increased weight amplitude slows down and blood fat
Decline, and it is various also decline to fat or related angiocardiopathy index, such as leptin (LEP) and monocyte chemotactic egg
- 1 (MCP-1) in vain.Therefore, heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its group
Close) can be to prevent and treat the fat and disease as caused by obesity, such as angiocardiopathy.
Composition and its application
Present invention also offers a kind of composition, it is preferable that is pharmaceutical composition.The composition includes the sheet of effective dose
The heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) of invention, in a preference, institute
State the probiotics that composition also includes being selected from the group：Lactic acid bacteria, Bifidobacterium, lactobacillus acidophilus or its combination；And/or be selected from
The prebiotics of the following group：It is FOS (FOS), galactooligosaccharide (GOS), xylo-oligosaccharide (XOS), lactosucrose (LACT), big
Beans oligosaccharide (SOS), inulin (Inulin) or its combination.
In a preference, described composition is liquid formulation, solid formulation, semisolid preparations.
In a preference, described liquid formulation is selected from the group：Solution product or suspension product.
In a preference, the formulation of described composition is selected from the group：Powder agent, powder, tablet, sugar-coat agent, capsule
Agent, granule, suspending agent, solution, syrup, drops and sublingual lozenge.
Pharmaceutical composition of the present invention can be with medicinal tablet, any form administration of injection or capsule, the medicine system
Agent includes the medium and carrier that excipient, medicine allow, and these materials can be selected according to method of administration.Medicine in the present invention
Preparation can further include the active constituent of auxiliary.
Lactose, glucose, sucrose, D-sorbite, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, silicon
Sour calcium, fine crystallization cellulose, polyvinylpyrrolidone (PVP), cellulose, water, syrup, methylcellulose, hydroxybenzoic acid first
Ester, nipasol, talcum, magnesium stearate or mineral oil etc. are used as the carrier of pharmaceutical composition in the present invention, tax
Shape agent or diluent etc..
In addition, the present invention pharmaceutical composition can further comprise lubricant, wetting agent, emulsifying agent, suspension stabiliser,
Preservative, sweetener and spices etc..The pharmaceutical composition of the present invention can be produced by a variety of known methods with enteric-coated preparations, with
Stomach can be passed through without being destroyed by hydrochloric acid in gastric juice by being easy to the active component i.e. microorganism of pharmaceutical composition.
In addition, the capsule form that the microorganism of the present invention can prepare in conventional manner is used.For example, standard excipients and sheet
The cold dry microorganism of invention is mixed and made into bead pill, and then pill is packed into gelatine capsule.In addition, micro- life of the present invention
Thing and medicine allow the excipient used such as liquid glue, cellulose, silicate or mineral oil etc. suspension to be made by mixing or scattered
Liquid, this suspension or dispersion liquid can be fitted into soft gelatine capsule.
The pharmaceutical composition of the present invention can be made into casing piece for being administered orally.Term-" casing " in the application, including
All conventional medicines allow the coating used, and these are coated not by gastric acid degradation, but can fully be decomposed and fast quick-release in small intestine
Release the microorganism of the present invention.The casing of wood invention can be small in 36-38 DEG C of maintenance 2 in synthesis hydrochloric acid in gastric juice such as pH=1 HCl solution
When more than, and preferably synthesis intestinal juice such as pH=7.0 buffer solution in 1.0 hours decomposition.
The casing of the present invention is to be coated with every agreement that contracts a film or TV play to an actor or actress 16-30mg, preferably 16-25mg, and more preferably 16-20mg is carried out
It is coated.Casing thickness is 5-100 μm in the present invention, and preferable thickness is 20-80 μm.Casing composition select oneself it is open know it is normal
Advise polymer.
Currently preferred casing by cellulosic phthalic acetate polymer or trimellitic acid ester polymer and
Methacrylate copolymer (for example, containing more than 40% methacrylate and containing methyl cellulose phthalate hydroxypropyl acrylate or
The copolymer of the methacrylate of its ester derivative) prepare.
The viscosity of cellulosic phthalic acetate used in casing is about 45-90cp, acetyl content in the present invention
17-26%, phthalate content 30-40%.It is about 5-21cp for the inclined ester of phthalic acid viscosity of cellulose acetate in casing,
Second phthalein content 17-26%.Cellulose acetate trimellitate is produced by Eastman Kodaks company, the intestines that can be used in the present invention
Clothing material.
Cruel for the hydroxypropyl methyl cellulose phthalic acid in casing of the present invention, molecular weight is generally 20,000-
130,000 dalton, desired molecular weight is 80,000-100,000 dalton, and hydroxypropyl content is 5-10%, methoxyl content
For 18-24%, phthalyl content is 21-35%.
It is extremely HP50 for the hydroxypropyl methyl cellulose phthalic acid in casing of the present invention, by Japanese Shin-Etsu
Chemidnl Co.Ltd. are produced.HP50 contains 6-10% hydroxypropyls, 20-24% methoxyl groups, 21-27% propyl group, its molecule
Measure as 84,000 dalton.Another Enteric materials are HP55, and HP55 contains 5-9% hydroxypropyl methyl cellulose O-phthalic
Acid esters, 18-22% methoxyl groups, 27-35% phthalic acid, its molecular weight is 78,000 dalton.
Casing of the present invention is prepared as follows：Casing solution is sprayed in core using conventional method.In the enteric coating method
All solvents are alcohols (such as ethanol), ketone (such as acetone), halogenated hydrocarbon compound (such as dichloromethane) or its composition.Will be soft
Agent such as di-n-butyl phthalic acid ester and glyceryl triacetate are added in casing solution, and its ratio is 1 part of coatings pair
About 0.05 part or about 0.3 part of softening agent.Spray method is preferably continuously performed, and the doses sprayed can be according to the used bar of coating
Part is controlled.Atomisation pressure can be adjusted arbitrarily, it is however generally that, preferable result can be obtained under average 1-1.5 handkerchiefs pressure.
In specification " medicine effective quantity " refer to that people and/or animal can be produced function or activity and can by people and/or
The amount that animal is received.Such as, in the present invention, it can prepare containing 1 × 10-1 × 1020Cfu/ml or cfu/g (particularly, can
Contain 1 × 104-1×1015Cfu/ml or cfu/g；More particularly, 1 × 10 can be contained6-1×1011Cfu/ml or cfu/g) sheet
The preparation of the heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) of invention.
When for preparing pharmaceutical composition, heavy wall mushroom probiotics (such as association fecal bacteria, muddiness of the invention used
Wear Alister bacterium or its combination) effective dose can change with the pattern of administration and the order of severity of disease to be treated.
Suitable for dosage form for oral administration, comprising with solid-state or the intimately mixed about 1 × 10-1 of liquid pharmaceutically acceptable carrier ×
1020Cfu/ml or cfu/g (particularly, can contain 1 × 104-1×1015Cfu/ml or cfu/g；More particularly, can containing 1 ×
106-1×1011Cfu/ml or cfu/g) active heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or
Its combine) active component.This dosage is can adjust to provide optimal treatment response.For example, by treatment situation it is urgent highly necessary
Ask, dosage separated several times can be given daily, or dosage is reduced pari passu.
Described heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can be by oral
Given etc. approach.Solid-state carrier includes：Starch, lactose, Dicalcium Phosphate, microcrystalline cellulose, sucrose and white bole, and liquid carrier
Including：Culture medium, polyethylene glycol, nonionic surface active agent and edible oil (such as corn oil, peanut oil and sesame oil), as long as
It is adapted to heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) characteristic and required specific administration
Mode.Usually used adjuvant also can be advantageously included in pharmaceutical composition is prepared, such as flavor enhancement, pigment, preservative
With antioxidant such as vitamin E, vitamin C, BHT and BHA.
In terms of easily prepared and administration position, pharmaceutical composition preferably is solid-state composition, especially tablet and solid
The capsule that body is filled or liquid is filled.Oral administration is preferred.
The present composition is administered to the individual, is administered once daily or repeatedly.Dosage unit represents its form
On can separate and suitable for the dosage of the mankind or other all mammalian subjects.Per unit contain medicine permission carrier and
The microorganism of the present invention of effective therapeutic dose.Dosage with patient body weight and the fat order of severity, included supplement activearm
Part and used microorganism and change.In addition as may, can separate and be administered, and if desired for can successive administration.Therefore, it is described
Dosage will not cause limitation to the present invention.In addition, " composition " in the present invention does not mean only that medicine and expression can be made
For functional food and healthy supplement.In a preference, the composition includes：Beverage, food, medicine, animal
Feed etc..
In the preference of the present invention, a kind of food compositions are additionally provided, it contains the heavy wall mushroom of effective dose
Probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its combination), and acceptable carrier on the food of surplus, institute
The formulation for the food composition stated is selected from solid, dairy products, solution product, pulverulent product or suspension product.
In a preference, the formula of the composition is as follows：
1×10-1×1020Cfu/mL heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its
Combination)；And on food or pharmaceutically acceptable carrier, and/or excipient.
In another preference, the formula of the composition is as follows：
1×106-1×1011Cfu/mL heavy wall mushroom probiotics (such as association fecal bacteria, muddiness wear Alister bacterium or its
Combination)；And on food or pharmaceutically acceptable carrier, and/or excipient.
Losing weight and/or the method for blood fat
In another preference, methods described includes：Absorb pharmaceutical composition, food compositions, the beverage group of the present invention
Compound or its combination.The experimental subjects is behaved.
In another preference, methods described includes：Absorb pharmaceutical composition, food compositions or the animal of the present invention
Feed, or its combination.The experimental subjects is animal, preferably muroid, Lagomorpha.
Main advantages of the present invention include：
(a) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Significantly reduce body weight, reduction blood fat, reduction body fat ratio.
(b) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Significantly reduce and fat and its related relevant disease (such as angiocardiopathy) index (such as cholesterol and triglycerides).
(c) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Significantly reduce the level of T-CHOL, triglycerides, low-density lipoprotein.
(d) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Significantly improve the level of HDL.
(e) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Improve insulin resistance, can also reduce the risk that atherosclerosis and angiocardiopathy occur.
(f) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Significantly reduce monocyte chemoattractant protein-1 (MCP-1) level.
(g) heavy wall mushroom probiotics of the invention (such as association fecal bacteria, muddiness wear Alister bacterium or its combination) can
Effectively improve the adjoint leptin resistance of obesity, improve the sensitiveness in vivo to Leptin.
With reference to specific embodiment, the present invention is expanded on further.It should be understood that these embodiments are merely to illustrate the present invention
Rather than limitation the scope of the present invention.The experimental method of unreceipted actual conditions in the following example, generally according to conventional strip
Part such as Sambrook et al., molecular cloning：Laboratory manual (New York：Cold Spring Harbor Laboratory
Press, 1989) described in condition, or according to《Microorganism：Laboratory manual》(James Cappuccino and Natalie
Sherman is compiled, Pearson Education publishing houses) described in condition, or according to the condition proposed by manufacturer.
The food compositions of the component containing bacterium of embodiment 1 (such as association fecal bacteria, muddiness wear Alister bacterium or its combination)
Raw material proportioning such as table 1.
The Combined food composition formula of table 1
| Raw material | Mass percent (%) |
| Bacterium component | 0.5 |
| Milk | 90.0 |
| White sugar | 9.5 |
The bacterium component being formulated in 1-6 is single bacteria component, respectively containing Coprococcus eutactus ATCC
27759、Coprococcus eutactus ATCC 51897、Coprococcus eutactus L2-50、Dialister
invisus DSM 15470、Dialister invisus E2.20、Dialister invisus E9.48。
Bacterium component in formula 7 is the mixture of any two or more (preferably 2 kinds or 3 kinds) of above-mentioned 6 kinds of bacterium
(weight ratio is 1:1 or 1:1:1).
According to above-mentioned formula rate mixing milk, white sugar, stirring is preheated, 20Mpa pressure homogeneous, 90 DEG C to being thoroughly mixed
Left and right is sterilized 5-10 minutes, is cooled to 40-43 DEG C, is inoculated with 1-100 × 106Cfu/g bacterium component, that is, be made component containing bacterium (such as
Association fecal bacteria, muddiness wear Alister bacterium or its combination) food compositions.
Embodiment 2
The pharmaceutical composition of component containing bacterium (such as association fecal bacteria, muddiness wear Alister bacterium or its combination)
Raw material proportioning is shown in Table 2.
The drug regimen composition formula of table 2
| Raw material | Mass percent (%) |
| Bacterium component | 1.0% |
| Lactose | 2.0% |
| Dusty yeast | 2.0% |
| Peptone | 1.0% |
| Pure water | 94.0% |
The bacterium component being formulated in 1-6 is single bacteria component, respectively containing Coprococcus eutactus ATCC
27759、Coprococcus eutactus ATCC 51897、Coprococcus eutactus L2-50、Dialister
invisus DSM 15470、Dialister invisus E2.20、Dialister invisus E9.48。
Bacterium component in formula 7 is the mixture of any two or more (preferably 2 kinds or 3 kinds) of above-mentioned 6 kinds of bacterium
(weight ratio is 1:1 or 1:1:1).Proportionally lactose, dusty yeast, peptone are well mixed with pure water, 60-65 is preheating to
DEG C, 20Mpa pressure homogeneous, 90 DEG C or so are sterilized 20-30 minutes, are cooled to 36-38 DEG C, access bacterium component (1-50 × 106cfu/
ML), 36-38 DEG C of fermentation to pH value is 6.0, and centrifugation, freeze-drying to water content is less than 3%, that is, is prepared into the component containing bacterium
It is freeze-dried thing.The freeze-drying thing of 0.5 gram of component containing bacterium is weighed with being fitted into after maltodextrin mixed in equal amounts in capsule, that is, is made
The pharmaceutical composition of component containing bacterium (such as association fecal bacteria, muddiness wear Alister bacterium or its combination).
Therapeutic action of the embodiment 3 for obese model mouse
Experiment material:
Mouse：C57BL/6J male mices (being purchased from Guangdong Medical Lab Animal Center) are bought, are normal raising mouse,
6 week old.Mouse growth process is in same environment, and feeds same food.
6 plants of heavy wall mushroom probiotics are obtained from preservation mechanism, and are stored in BGI-Shenzhen.Meanwhile, choose
Lactobacillus plantarum (Lactobacillus plantarum), from the common micro- life of China Committee for Culture Collection of Microorganisms
Thing center (CGMCC), deposit number CGMCC No.8198, as a control group (LP groups), and in MRS nutrient solutions, 37 DEG C of cultures
24-48h。
Wherein, the source-information of above-mentioned 6 plants of heavy walls mushroom probiotics is as shown in table 3.All bacterial strains are sequenced through 16S rDNA
Start experiment after identification is errorless.
Bacterial strain information is shown in Table 3.
The bacterial strain information of table 3
Wherein, Coprococcus eutactus L2-50 (bacterium 3) derive from Britain sieve Witter research institute (Rowett
Research Institute)(Barcenilla A,Pryde SE,Martin JC et al.Phylogenetic
Relationships of Butyrate-Producing Bacteria from the Human Gut.Applied and
Environmental Microbiology 2000；66:1654-1661.).Dialister invisus E2.20 (bacterium 5) and
Dialister invisus E9.48 (bacterium 6) derive from dentistry research institute of Gai Shi hospitals of London King's College microorganism
Section (Department of Microbiology, Dental Institute, Guy's Tower, Guy's Hospital,
King's College London,UK；J.Downes, M.Munson and W.G.Wade, Dialister invisus
sp.nov.,isolated from the human oral cavity,International Journal of
Systematic and Evolutionary Microbiology(2003),53,1937–1940)。
High lipid food (HF)：Containing 78.8% basal feed, 1% cholesterol, 10% yolk powder, 10% lard and 0.2% courage
Salt, purchased from Nantong Te Luofei feed technologies Co., Ltd.
It is common to maintain feed：Purchased from Guangdong Medical Lab Animal Center.
Experimental method：
Choose the C57BL/6J adult male mices normally fed, respectively random packet, control group (CK), microbial inoculum group
(1 group of bacterium, 2 groups of bacterium, 3 groups of bacterium, 4 groups of bacterium, 5 groups of bacterium, 6 groups of bacterium, 5 groups of bacterium 1+ bacterium, 6 groups of bacterium 2+ bacterium, 4 groups of bacterium 3+ bacterium), compares microbial inoculum
Group (LP, Lactobacillus plantarum CGMCC No.8198) and obese model group (HF), every group 10, in SPF
Ad lib and drinking-water under (no-special pathogen (Specific pathogen Free)) environment.LP groups, HF groups and microbial inoculum group
Feeding high lipid food, CK group feedings commonly maintain feed.Feed after 4 weeks, microbial inoculum group and LP groups start the corresponding bacterial strain bacterium solution of gavage；
HF groups and CK group gavage equivalent culture mediums, gavage 9 weeks.
Feed bacterium amount and be set to 0.15mL/10g body weight, dense bacterium is 1 × 107Concentration is 1 × 10 after cfu/mL, concentration8cfu/
ML, frequency is once every other day.Bacterium solution need to be cultivated in advance, and activation weekly ensures fresh, determines concentration respectively, and adjust to 1 ×
108cfu/mL.For single microbial inoculum group, corresponding bacterium solution is taken by above-mentioned dosage gavage；For mix bacterium agent group, by each single bacterium bacterium solution
Above-mentioned dosage gavage is pressed after equal proportion mixing.
In experiment periods, the data such as mouse weight, state, food-intake are recorded weekly.Test each group mouse progress in last week
Glucose tolerance (OGTT) is tested.Mouse is put to death in experiment after terminating, record fat weight, and takes serum, is examined with Elisa kits
Survey blood fat and protein factor content.
Experimental result：
(1) association fecal bacteria, muddiness wear the influence of Alister bacterium or its combination strain to mouse body weight.
Body weight increase situation (Fig. 1) of each group mouse compared with before gavage after the gavage association fecal bacteria of table 4
Note：Data are mean+SD in table, for any two groups of data of each row, not identical behind numeral
Letter represents significant difference (p<0.05), table 5-15 is identical with this.
The gavage muddiness of table 5 wears body weight increase situation (Fig. 2) of each group mouse compared with before gavage after Alister bacterium
Body weight increase situation (Fig. 3) of each group mouse compared with before gavage after the gavage combination strain of table 6
As a result as shown in table 4-6 and Fig. 1-3.As a result show, association fecal bacteria, muddiness wear Alister bacterium or its combination
Growth (the P of the body weight of obese model mouse can effectively be slowed down<0.05).
(2) association fecal bacteria, it is muddy wear Alister bacterium or its combination strain to body fat than influence.
The body fat ratio (Fig. 4) of the gavage association fecal bacteria of table 7 each group mouse after 9 weeks
| Packet | Fat weight/body weight × 100% |
| CK | 2.83±0.13e |
| Bacterium 1 | 4.11±0.10c |
| Bacterium 2 | 4.00±0.26cd |
| Bacterium 3 | 3.85±0.19d |
| LP | 5.39±0.34b |
| HF | 7.48±0.46a |
The gavage muddiness of table 8 wears the body fat ratio (Fig. 5) of Alister bacterium each group mouse after 9 weeks
| Packet | Fat weight/body weight × 100% |
| CK | 2.91±0.14e |
| Bacterium 4 | 3.97±0.22cd |
| Bacterium 5 | 4.16±0.23c |
| Bacterium 6 | 3.76±0.20d |
| LP | 5.21±0.24b |
| HF | 746±064a |
The body fat ratio (Fig. 6) of 9 gavage combination strain of table each group mouse after 9 weeks
| Packet | Fat weight/body weight × 100% |
| CK | 2.90±0.13d |
| Bacterium 1+5 | 3.73±0.19c |
| Bacterium 2+6 | 3.87±0.23c |
| Bacterium 3+4 | 3.93±0.22c |
| LP | 5.42±0.17b |
| HF | 756±055a |
As a result as shown in table 7-9 and Fig. 4-6.As a result show, association fecal bacteria, muddiness wear Alister bacterium or its combination strain
Body fat ratio (the P of obese model mouse can be significantly reduced<0.05).
(3) association fecal bacteria, muddiness wear the influence of Alister bacterium or its combination strain to blood fat.
The gavage association fecal bacteria of table 10 each group lipid of mice content (Fig. 7) after 9 weeks
| Packet | TC(mmol/L) | TG(mmol/L) | LDLC(mmol/L) | HDLC(mmol/L) |
| CK | 3.811±0.144d | 0.914±0.048d | 1.260±0.057e | 3.354±0.166a |
| Bacterium 1 | 4.819±0.198c | 1.041±0.080c | 1.516±0.084c | 3.529±0.123a |
| Bacterium 2 | 4.790±0.226c | 1.052±0.059c | 1.479±0.083cd | 3.510±0.160a |
| Bacterium 3 | 4.823±0.251c | 1.073±0.057c | 1.457±0.102d | 3.479±0.158a |
| LP | 5.385±0.253b | 1.234±0.094b | 1.872±0.124b | 2.743±0.139b |
| HF | 6299±0257a | 1303±0076a | 2381±0157a | 2193±0104c |
The gavage muddiness of table 11 wears Alister bacterium each group lipid of mice content (Fig. 8) after 9 weeks
| Packet | TC(mmol/L) | TG(mmol/L) | LDLC(mmol/L) | HDLC(mmol/L) |
| CK | 3.892±0.154d | 0.983±0.047c | 1.250±0.036d | 3.376±0.202a |
| Bacterium 4 | 4.896±0.230c | 1.012±0.072c | 1.395±0.082c | 3.497±0.093a |
| Bacterium 5 | 4.906±0.247c | 1.014±0.054c | 1.353±0.076c | 3.439±0.160a |
| Bacterium 6 | 4.917±0.201c | 1.069±0.070c | 1.364±0.071c | 3.421±0.195a |
| LP | 5.258±0.302b | 1.216±0.088b | 1.831±0.131b | 2.741±0.100b |
| HF | 6.390±0.290a | 1.295±0.064a | 2.357±0.126a | 2.153±0.105c |
12 gavage combination strain of table each group lipid of mice content (Fig. 9) after 9 weeks
| Packet | TC(mmol/L) | TG(mmol/L) | LDLC(mmol/L) | HDLC(mmol/L) |
| CK | 3.902±0.111d | 0.964±0.046d | 1.213±0.060d | 3.287±0.239a |
| Bacterium 1+5 | 4.822±0.139c | 1.019±0.067c | 1.369±0.077c | 3.324±0.177a |
| Bacterium 2+6 | 4.904±0.182c | 1.017±0.061c | 1.367±0.077c | 3.249±0.215a |
| Bacterium 3+4 | 4.834±0.192c | 1.009±0.060c | 1.381±0.082c | 3.252±0.140a |
| LP | 5.498±0.280b | 1.213±0.061b | 1.742±0.105b | 2.621±0.106b |
| HF | 6.511±0.252a | 1.304±0.094a | 2.357±0.166a | 2.196±0.096c |
As a result as shown in Fig. 7-9 and table 10-12.Main Ingredients and Appearance in blood fat is courage in cholesterol and triglycerides, blood plasma
The rise of sterol and triglyceride level is relevant with the generation of atherosclerosis.As a result show, association fecal bacteria, muddiness wear Ah
Li Site bacterium or its combination strain can reduce blood fat, and the correlation of reduction atherosclerosis relevant disease (such as angiocardiopathy) refers to
Mark.Also, association fecal bacteria, muddiness wear Alister bacterium or its combination strain reduction T-CHOL (TC), total triglycerides (TG)
With low-density lipoprotein (LDLC), and increase HDL (HDLC) particularly evident (P of effect<0.05).
(4) association fecal bacteria, muddiness wear Alister bacterium or its combination strain leptin (Leptin, LEP), monocyte are become
Change the influence of albumen -1 (MCP-1).
The gavage association fecal bacteria of table 13 each group mouse Leptin (Leptin, LEP), monocyte chemoattractant protein-1 after 9 weeks
(MCP-1) content (Figure 10, Figure 13)
The gavage muddiness of table 14 wears Alister bacterium each group mouse Leptin (Leptin, LEP), monocyte chemotactic egg after 9 weeks
- 1 (MCP-1) content (Figure 11, Figure 14) in vain
| Packet | MCP-1(pg/ml) | LEP(pg/ml) |
| CK | 343.07±44.17c | 1162.93±96.41c |
| Bacterium 4 | 339.99±39.03c | 1158.48±130.63c |
| Bacterium 5 | 338.79±31.89c | 1166.22±136.26c |
| Bacterium 6 | 336.81±38.48c | 1158.43±111.51c |
| LP | 365.95±48.92b | 1264.09±158.29b |
| HF | 383.04±45.92a | 1401.25±147.52a |
15 gavage combination strain of table each group mouse Leptin (Leptin, LEP), monocyte chemoattractant protein-1 (MCP-1) after 9 weeks
Content (Figure 12, Figure 15)
| Packet | MCP-1(pg/ml) | LEP(pg/ml) |
| CK | 336.55±38.88c | 1164.35±106.96c |
| Bacterium 1+5 | 335.85±31.27c | 1173.25±114.83c |
| Bacterium 2+6 | 333.48±31.21c | 1169.25±132.61c |
| Bacterium 3+4 | 330.36±35.21c | 1176.85±109.40c |
| LP | 366.47±24.75b | 1259.06±144.03b |
| HF | 384.12±44.29a | 1401.18±179.66a |
As a result as shown in Figure 10-15 and table 13-15.As a result show, association fecal bacteria, muddiness wear Alister bacterium or its group
The content of leptin (LEP) and monocyte chemoattractant protein-1 (MCP-1) in obese model mice serum can substantially be reduced by closing bacterium
(P<0.05)。
As a result show, association fecal bacteria, muddiness wear Alister bacterium or its combination strain can improve leptin resistance, improve body
The interior sensitiveness to leptin (LEP)；Also, the blood after association fecal bacteria, muddiness wear Alister bacterium or the treatment of its combination strain
Clear MCP-1 levels reduction, is conducive to improving insulin resistance, it is possible to decrease the wind that atherosclerosis and angiocardiopathy occur
Danger.
All documents referred in the present invention are all incorporated as reference in this application, independent just as each document
It is incorporated as with reference to such.In addition, it is to be understood that after the above-mentioned instruction content of the present invention has been read, those skilled in the art can
To be made various changes or modifications to the present invention, these equivalent form of values equally fall within the model that the application appended claims are limited
Enclose.
Claims (10)
1. a kind of purposes of heavy wall mushroom probiotics, it is characterised in that for preparing composition or preparation, the composition or system
Agent is used for the one or more purposes being selected from the group：(a) prevent and/or treat fat；(b) blood fat is reduced；(c) prevent or treat
Angiocardiopathy；And/or (d) prevention and/or treatment diabetes, wherein, the heavy wall mushroom probiotics is selected from the group：Association excrement
Coccus (Coprococcus eutactus), muddiness wear Alister bacterium (Dialister invisus) or its combination.
2. purposes as claimed in claim 1, it is characterised in that the heavy wall mushroom probiotics includes association fecal bacteria
(Coprococcus eutactus)。
3. purposes as claimed in claim 2, it is characterised in that association fecal bacteria (Coprococcus eutactus) choosing
From the following group：Coprococcus eutactus ATCC 27759、Coprococcus eutactus ATCC 51897、
Coprococcus eutactus L2-50 or its combination.
4. a kind of purposes of heavy wall mushroom probiotics, it is characterised in that for preparing composition or preparation, the composition or system
Agent is used for the one or more purposes being selected from the group：(i) water of monocyte chemoattractant protein-1 (MCP-1) in mammal is reduced
It is flat；And/or (ii) improves leptin resistance, the sensitiveness in vivo to Leptin is improved, wherein, the heavy wall mushroom probiotics is selected from
The following group：Association fecal bacteria (Coprococcus eutactus), muddiness wear Alister bacterium (Dialister invisus) or
It is combined.
5. purposes as claimed in claim 4, it is characterised in that the composition or preparation are also independently or additionally used to select
From one or more purposes of the following group：
(iii) body weight increase of mammal is suppressed；
(iv) the body fat ratio (the ratio between fat weight/body weight) of mammal is reduced；
(v) blood lipid level of mammal is reduced；
(vi) level of the HDL (HDLC) in mammal is improved；
(vii) low-density lipoprotein (LDLC) level in reduction mammal.
6. a kind of be used for the composition for the treatment of and/or pre- preventing obesity, the composition includes：(i) firmicutes of safe and effective amount
Class probiotics；On (ii) food or pharmaceutically acceptable carrier；Wherein, the heavy wall mushroom probiotics is selected from the group：Companion
Raw fecal bacteria (Coprococcus eutactus), muddiness wear Alister bacterium (Dialister invisus) or its combination.
7. composition as claimed in claim 6, it is characterised in that the composition contains 1 × 10-1 × 1020Cfu/mL or
Cfu/g heavy wall mushroom probiotics, preferably 1 × 104-1×1015Cfu/mL or cfu/g heavy wall mushroom probiotics, by described
The cumulative volume or gross weight meter of composition.
8. composition as claimed in claim 6, it is characterised in that in described composition, containing 0.0001-99wt%, compared with
Heavy wall mushroom probiotics described in good ground 0.1-90wt%, with the gross weight meter of the composition.
9. composition as claimed in claim 6, it is characterised in that described composition also contains other probiotics and/or benefit
Raw member.
10. the preparation method of composition described in a kind of claim 6, including step：
Mixed by (i) heavy wall mushroom probiotics, with acceptable carrier or pharmaceutically acceptable carrier on (ii) food, so that
Form the composition described in claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610032106.9A CN106974940B (en) | 2016-01-15 | 2016-01-15 | Application of probiotics of scleritis in treating and preventing obesity and related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610032106.9A CN106974940B (en) | 2016-01-15 | 2016-01-15 | Application of probiotics of scleritis in treating and preventing obesity and related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106974940A true CN106974940A (en) | 2017-07-25 |
| CN106974940B CN106974940B (en) | 2020-08-25 |
Family
ID=59340610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610032106.9A Active CN106974940B (en) | 2016-01-15 | 2016-01-15 | Application of probiotics of scleritis in treating and preventing obesity and related diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974940B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114246886A (en) * | 2021-12-24 | 2022-03-29 | 山西大学 | Application of regular faecalis in the preparation of preparations for preventing and treating acute colitis |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| WO2013037068A1 (en) * | 2011-09-14 | 2013-03-21 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| WO2014121302A2 (en) * | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| WO2015077794A1 (en) * | 2013-11-25 | 2015-05-28 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| WO2015181449A1 (en) * | 2014-05-28 | 2015-12-03 | Neuroinnovation Oy | Method for diagnostics, treatment and prevention of parkinson's disease |
| CN107949391A (en) * | 2015-05-14 | 2018-04-20 | 克雷斯顿沃控股公司 | For faecal microbiota transplanting composition and be used to prepare and using they method and for delivering their device |
| CN108064132A (en) * | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | The method and composition related with the antimicrobial treatments of illness and diagnosis |
| CN108135944A (en) * | 2014-11-25 | 2018-06-08 | 伊夫罗生物科学公司 | Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group |
-
2016
- 2016-01-15 CN CN201610032106.9A patent/CN106974940B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| WO2013037068A1 (en) * | 2011-09-14 | 2013-03-21 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| WO2014121302A2 (en) * | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| WO2015077794A1 (en) * | 2013-11-25 | 2015-05-28 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| WO2015181449A1 (en) * | 2014-05-28 | 2015-12-03 | Neuroinnovation Oy | Method for diagnostics, treatment and prevention of parkinson's disease |
| CN108064132A (en) * | 2014-10-31 | 2018-05-22 | 霍勒拜欧姆公司 | The method and composition related with the antimicrobial treatments of illness and diagnosis |
| CN108135944A (en) * | 2014-11-25 | 2018-06-08 | 伊夫罗生物科学公司 | Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group |
| CN107949391A (en) * | 2015-05-14 | 2018-04-20 | 克雷斯顿沃控股公司 | For faecal microbiota transplanting composition and be used to prepare and using they method and for delivering their device |
Non-Patent Citations (1)
| Title |
|---|
| ALEKSANDAR D. KOSTIC等: "The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes", 《CELL HOST & MICROBE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114246886A (en) * | 2021-12-24 | 2022-03-29 | 山西大学 | Application of regular faecalis in the preparation of preparations for preventing and treating acute colitis |
| CN114246886B (en) * | 2021-12-24 | 2023-05-30 | 山西大学 | Application of enterococcus faecalis in preparation for preventing and treating acute colitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106974940B (en) | 2020-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| CN103082292B (en) | Use of Roseburia for the treatment and prevention of obesity-related diseases | |
| US20240342226A1 (en) | Probiotic Bacterial Strains That Produce Short Chain Fatty Acids And Compositions Comprising Same | |
| CN109451727A (en) | The composition and its preparation and application of probiotics and digestive ferment | |
| US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN110325198A (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| CN103908585A (en) | Probiotic fermentation composition used for preventing and treating constipation | |
| US20210170009A1 (en) | Intestinal bacteria butyribacterintestini and application thereof | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| CN109419816B (en) | Application of bacteroides cellulolyticus in preventing and/or treating heart diseases | |
| CN106994134B (en) | Application of intestinal probiotics in prevention and/or treatment of diabetes and related diseases thereof | |
| DE102010009582A1 (en) | Agent for use in lactase deficiency and lactose intolerance | |
| CN104432001A (en) | Edible composition and use thereof | |
| US20100330128A1 (en) | Method of improving immune function in mammals using lactobacillus strains with certain lipids | |
| CN109504615A (en) | Simple form Megamonas (Megamonas funiformis) and its application | |
| CN106852938A (en) | Application of the bacteroid (Bacteroides) in obesity-related disease is treated and prevented | |
| US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN107028985A (en) | Application of the heavy wall mushroom probiotics in preventing and/or treating diabetes and its relevant disease | |
| EP3721889B1 (en) | Butyribacter intestini for use in preventing and/or treating inflammatory bowel disease | |
| CN106974940A (en) | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented | |
| CN106974939B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| JPH10298083A (en) | Composition for treating hyperlipidemia and food for hyperlipidemia | |
| Bingham | Functional foods: dietary intervention strategies in autistic spectrum disorders | |
| CN107080756B (en) | Use of probiotic bacteria of the genus streptococcus for the prevention and/or treatment of diabetes and related diseases | |
| CN117343869A (en) | Application of bifidobacterium animalis in preparation of products for reducing complications after heart valve operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1239568 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: Beishan Industrial Zone Building in Yantian District of Shenzhen city of Guangdong Province in 518083 Applicant after: BGI SHENZHEN Address before: Beishan Industrial Zone Building in Yantian District of Shenzhen city of Guangdong Province in 518083 Applicant before: BGI SHENZHEN |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |